Neuralstem (NASDAQ:CUR) stock is on fire after revealing a huge clinical win that has sent bulls storming the market today to buy into …
Neuralstem, Inc. (NYSE MKT:CUR), a biopharmaceutical company using neural stem cell technology to develop small molecule and cell therapy treatments for central nervous …
Neuralstem, Inc. (NYSE MKT:CUR) a biopharmaceutical company using neural stem cell technology to develop small molecule and cell therapy treatments for central nervous …
Neuralstem, Inc. (NYSE MKT: CUR) reported its financial results for the fourth quarter and year ended December 31, 2014.
Neuralstem, Inc. (NYSE MKT: CUR) announced top line data from the Phase II trial of NSI-566 spinal cord-derived neural stem cells under development for …
In a research report issued this morning, Brean Capital analyst Jonathan Aschoff initiated coverage on shares of Neuralstem (NYSE:CUR) with a Buy rating and …
In a research report sent to investors today, H.C.
In a research report issued today, H.C.